title: [Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].
abstract: OBJECTIVE
  The present study describes two patients with retroperitoneal fibrosis following prolonged use of bromocriptine and pergolide for Parkinson's disease. Both patients also presented severe atheromatosis.
  
  
  METHODS
  Similar cases reported in the literature are reviewed and the possible relationship between the use of the ergotamine derivate and severe atheromatosis is discussed.
  
  
  RESULTS
  Both patients, a 67-year-old male and a 62-year-old female, improved after discontinuing bromocriptine, despite severe damage of renal function.
  
  
  CONCLUSIONS
  Retroperitoneal fibrosis may develop in patients with bilateral ureteral obstruction, especially those who have received drugs that have been reported to cause the foregoing condition.
authors.affiliation: Servicio de Urología, Hospital Principe de Asturias, Facultad de Medicina, Universidad de Alcalá de Henares, Madrid.
authors.forename: M
authors.initials: M
authors.lastname: Sánchez-Chapado
authors.forename: J
authors.initials: J
authors.lastname: Angulo Cuesta
authors.forename: M
authors.initials: M
authors.lastname: Guil Cid
authors.forename: F J
authors.initials: FJ
authors.lastname: Jiménez
authors.forename: Y J
authors.initials: YJ
authors.lastname: López Alvarez
mesh_terms: D000368:Aged; D001971:Bromocriptine / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy; D010479:Pergolide / Q000009:adverse effects*; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced*
chemical_list: D018491:Dopamine Agonists; D010479:Pergolide; D001971:Bromocriptine